The oncogenic role of TCL1 in chronic lymphocytic leukemia is well established in transgenic mice. TCL1 expression in other B-cell malignancies has been also described: post-germinal center-derived malignancies, such as multiple myeloma, classically do not express TCL1. Waldenström macroglobulinemia is a post-germinal center malignancy that is known to be similar to chronic lymphocytic leukemia in terms of its gene expression profile. TCL1 expression has not been so far assessed in Waldenström macroglobulinemia. Transcriptomic explorations show that TCL1A expression is linked to signaling pathways and biological functions that are known to be involved in Waldenström macroglobulinemia as well as to gene signatures of interest in B-cell malignancies. We investigated TCL1 expression at the protein level in the bone marrow of a series of 59 patients with Waldenström macroglobulinemia: 76% of patients expressed TCL1, which appeared to be associated with a pejorative prognostic impact. TCL1 could have an oncogenic role in Waldenström macroglobulinemia, and deserves further exploration.
The oncogenic role of TCL1 in chronic lymphocytic leukemia is well established in transgenic mice. TCL1 expression in other B-cell malignancies has been also described: post-germinal center-derived malignancies, such as multiple myeloma, classically do not express TCL1. Waldenström macroglobulinemia is a post-germinal center malignancy that is known to be similar to chronic lymphocytic leukemia in terms of its gene expression profile. TCL1 expression has not been so far assessed in Waldenström macroglobulinemia. Transcriptomic explorations show that TCL1A expression is linked to signaling pathways and biological functions that are known to be involved in Waldenström macroglobulinemia as well as to gene signatures of interest in B-cell malignancies. We investigated TCL1 expression at the protein level in the bone marrow of a series of 59 patients with Waldenström macroglobulinemia: 76% of patients expressed TCL1, which appeared to be associated with a pejorative prognostic impact. TCL1 could have an oncogenic role in Waldenström macroglobulinemia, and deserves further exploration. Modern Pathology (2016) 29, 83-88; doi:10.1038/modpathol.2015.122; published online 23 October 2015 Waldenström macroglobulinemia is an uncommon B-cell lymphoproliferative disorder characterized by lymphoplasmacytic cells that infiltrate the bone marrow, along with the presence of an immunoglobulin M monoclonal protein in the serum. 1 Waldenström macroglobulinemia is thought to be derived from B cells in which differentiation has been arrested after a somatic hypermutation process in the germinal center and before terminal maturation into plasma cells. 2 Oncogenesis may be a result of dysregulation of the NF-κB and PI3K/Akt/ mTOR signaling pathways, [3] [4] [5] and from the influence of the bone marrow microenvironment. 6, 7 Furthermore, whole-genome sequencing of Waldenström macroglobulinemia patients has recently uncovered highly recurring MYD88 L265P and WHIM-like CXCR4 mutations that have a potential role in such pathways. 8, 9 The T-cell leukemia/lymphoma 1 (TCL1) protein encoded by the TCL1A gene (TCL1) is normally expressed during the early steps of B-and T-cell lymphopoiesis. 10 TCL1 has been shown to be overexpressed in chronic lymphocytic leukemia, 11, 12 and its oncogenic role has been well established in transgenic mice. 13 It acts as an activator of Akt 14 and NF-kB 15 signaling in the cytoplasm, but may also function as a transcriptional regulator in the nucleus. 16 Increased TCL1 expression has been observed in other B-cell disorders 17, 18 but not in multiple myeloma. TCL1 expression level still needs to be investigated in Waldenström macroglobulinemia and is the focus of this report.
Materials and methods

Analysis of Transcriptomic Datasets
Transcriptomic data were obtained from native data taken from two publicly available datasets (GSE6691 and GSE12668 datasets). The GSE6691 GEO dataset (56 samples) provided insight into the differences between cells from Waldenström macroglobulinemia and their cell counterparts in chronic lymphocytic leukemia and multiple myeloma. These data were analyzed to compare respective TCL1A expressions in these disease entities using the GEO2R tool from NCBI. The GSE12668 dataset (22 samples) provided high-resolution genomic analysis of Waldenström macroglobulinemia. These data were analyzed to assess TCL1A-co-regulated genes in Waldenström macroglobulinemia. We performed a new normalization procedure to check the intrinsic qualities of the native data: gene expression levels were normalized using the GC Robust Multi-array Average algorithm and flags were computed using MAS5. Quality assessment of the chips was performed using the affyQC-Report R package. Cluster analysis was performed by hierarchical clustering using Spearman's correlation of similarity measure and an average-linkage algorithm. Data were analyzed using QIAGEN's Ingenuity Pathway Analysis, 19 which assessed the relationships between genes and proteins, and constructed pathways to unveil the relevant biological processes.
Patients and Samples
Fifty-nine patients who underwent a bone marrow trephine biopsy for Waldenström macroglobulinemia, at Clermont-Ferrand and La Pitié-Salpêtrière University Hospitals between 1998 and 2012, were included in accordance with the Declaration of Helsinki. All included patients presented with Waldenström macroglobulinemia as defined by the international guidelines according to the World Health Organization classification 20 and the Second International Workshop on Waldenström's Macroglobulinemia, 1 ie, bone marrow infiltrated by immunoglobulin M producing clonal lymphoplasmacytic lymphoma. All patients were treated according to the Athens criteria. 1 Their characteristics are shown in Table 1 . The median follow-up was 103 months (6-261 months).
Immunohistochemistry and Scoring
Analyses were performed in the Clermont-Ferrand pathology laboratory using monoclonal mouse antihuman TCL1 antibody (Clone 27D6/20; MBL International Corporation, Des Plaines, IL, USA; 1/100 dilution for 1 h) and monoclonal mouse anti-human CD20 antibody (Clone L26; Dako, Carpinteria, CA, USA; 1/100 dilution for 1 h). Immunostaining was assessed by three independent investigators who were blinded to the clinical data. If there was disagreement, a second review was conducted.
To assess the tumor infiltrates (stained by hematoxylin and eosin, and by anti-CD20 antibody), the percentage of TCL1-stained tumor cells was determined using a previously published four-tier scoring system for TCL1 assessment in B-cell malignancies, 11, 17 as follows: 0 = negative; 1 = o 5% of tumor cells positive; 2 = positive in up to 50% of tumor cells; and 3 = positive in 450% of tumor cells. TCL1 staining intensity was also recorded using a previously published three-tier score (0 = no staining; 1 = low intensity; 2 = high intensity) 11 to evaluate the intra-tumoral distribution and level of TCL1 expression within each tumor sample.
Statistical Analyses
Therapeutic requirements and the time until endpoints were defined according to published recommendations. 1, 21, 22 Pearson Chi-square test, two-sided Fisher test, Mann-Whitney test, Kaplan-Meier method, and log-rank test were applied to the data in appropriate settings, using SPSS Statistics v22 (IBM), PRISM v6.0 (Graphpad), and/or R 23 software.
Results
TCL1A Expression and Related Transcriptome
To investigate the potential role of TCL1 in the biology of Waldenström macroglobulinemia, we first analyzed publicly available transcriptomic datasets. Analyses of data from GSE6691 showed that TCL1A mRNA expression levels of Waldenström macroglobulinemia cells ranged from those observed in multiple myeloma to those observed in chronic lymphocytic leukemia (P o 0.001) (Figure 1a) . In order to analyze TCL1-related transcriptome, we defined two groups of patients according to TCL1A expression using the GSE12668 dataset: ie, a TCL1A low group with normalized fluorescence of TCL1 in Waldenström macroglobulinemia 285 (o 25th percentile) and a TCL1A high group with normalized fluorescence of 3186 (475 th percentile).
We checked that median TCL1A expression in the TCL1A low group was 10-fold higher than the background noise and that TCL1A expression was significantly different between both groups (mean TCL1A high /TCL1A low ratio of 11, and a mean delta (TCL1A high -TCL1A low ) of 2901) (P o 0.001). We then compared the gene expression profile related to each group (TCL1A high vs TCL1A low ).
Consistent with the oncogenic role of TCL1, most relevant signaling pathways associated with TCL1A high expression are known to be involved in cell cycle, apoptosis, and the DNA-damage response. Interestingly, TCL1A high expression was associated with signaling pathways previously shown to be relevant in Waldenström macroglobulinemia (ie, PI3K/AKT, mTOR, BCR signal 3-5 ) (Figure 1b) . The highlighted biological functions related to TCL1A agreed with these results (Supplementary Table 1 ). In addition, TCL1A high was associated with gene signatures of interest in tumor B-cell progression or resistance (eg, activated MYC, CCND1, SOX11 signatures, and an inhibited TP53 signature) (Supplementary Table 2 ).
By computing these data and using published data on TCL1A, we explored the putative interactions of TCL1A in Waldenström macroglobulinemia tumor cells. TCL1A could be linked to crucial actors in the pathophysiology of Waldenström macroglobulinemia within a tightly coupled network (Figure 1c) .
Impact of TCL1 Protein Expression on Survival
Immunostaining of bone marrow tumor cells revealed that TCL1 was expressed at the protein level in 45 (76%) Waldenström macroglobulinemia patients. This expression was weak in 2, moderate in 17, and strong in 26 patients (Figure 2a) . TCL1 was preferentially detected in the cytoplasm compared with the nucleus.
Regarding the clinical relevance of TCL1 expression in Waldenström macroglobulinemia, we failed to demonstrate any significant correlation between TCL1 expression pattern and the Waldenström macroglobulinemia features known to affect the prognosis (Table 1) . However, patients with moderate/strong TCL1 expression had a significantly shorter time to next treatment compared with patients with negative/ weak expression (16.4 vs 59.4 months, respectively; HR 2.07 (95% CI: 1.037-3.692), P = 0.036) (Figure 2b ). No significant impact was observed in terms of progression-free survival or overall survival.
Discussion
Herein, for the first time, we have highlighted the expression of the TCL1 oncogene in Waldenström macroglobulinemia. The TCL1 transcriptomic targets were in line with the biology of Waldenström macroglobulinemia, and high TCL1 expression was associated with a poor outcome.
Using analyses from transcriptomic datasets, we found that TCL1 expression levels ranged from those observed in multiple myeloma to those observed in chronic lymphocytic leukemia. Moreover, gene expression profiles related to TCL1 gene expression were similar to the gene signatures of interest in B-cell malignancies, and corresponded to the biological pathways involved in cell cycle, apoptosis, and the DNA-damage response, which are known to be implicated in Waldenström macroglobulinemia oncogenesis. Altogether, these results suggest that TCL1 could have an oncogenic role in Waldenström macroglobulinemia. 
TCL1 in Waldenström macroglobulinemia
Most patients expressed TCL1 at a protein level. Moreover, the high percentage of tumor cells that expressed TCL1 was linked to a poor outcome but was not associated with classical agressive features. Interestingly, staining intensity was heterogeneous within the tumor infiltrates, as has been described in chronic lymphocytic leukemia, 11 which questions the mechanisms underlying TCL1 overexpression in Waldenström macroglobulinemia.
TCL1 was preferentially detected in the cytoplasm compared with the nucleus: this has also been observed in Burkitt's lymphoma, but both cytoplasmic and nuclear localization were then seen in pre-germinal center B-cell lymphoma. 17 On the basis of these observations, two major issues have to be addressed. First, the published data indicate that TCL1 is not expressed in patients with marginal-zone lymphoma. 17, 24 Differential diagnosis of Waldenström macroglobulinemia with marginalzone lymphoma can be challenging, and its diagnosis directly impacts on the choice of therapeutic options. Our data suggest that TCL1 expression could be a differential marker between Waldenström macroglobulinemia and marginal-zone lymphoma, although this remains to be explored further. In addition, if TCL1 expression can clearly distinguish Waldenström macroglobulinemia from other B-cell malignancies, including marginal-zone lymphoma and multiple myeloma, such a difference, as demonstrated by the MYD88 L265P mutation, could provide important insights regarding the specific patterns of tumor development in Waldenström macroglobulinemia.
Overall, our results indicate that the TCL1 oncogene is significantly expressed in most of Waldenström macroglobulinemia cases, in which it could drive important pathways and adversely impact on prognosis. Added value of TCL1 staining for Waldenström macroglobulinemia diagnosis remains to be investigated.
